Core Viewpoint - The National Medical Products Administration (NMPA) is optimizing the review and approval process for urgently needed foreign drugs already on the market to meet the pressing clinical needs of patients in China [1][2]. Group 1: Regulatory Changes - The NMPA will enhance the review mechanism and accelerate the review speed while improving the inspection system to reflect the characteristics of various drug types [2]. - The NMPA encourages applicants to conduct global synchronous research and simultaneous application for market approval in China for urgently needed foreign drugs [1]. Group 2: Market Performance - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024 [2]. - The total amount of authorized transactions for innovative drugs in 2025 exceeded $130 billion, with over 150 transactions, marking another historical high [2]. Group 3: Drug Composition - The 76 innovative drugs approved in 2025 include 47 chemical drugs, 23 biological products, and 6 traditional Chinese medicines [2]. - Among the 47 chemical drugs, 38 are domestic innovations, and 9 are imported, with domestic innovations accounting for 80.85% [2]. - For the 23 biological products, 21 are domestic innovations, and 2 are imported, with domestic innovations making up 91.30% [2]. Group 4: Industry Outlook - The release of the first version of the "Commercial Health Insurance Innovative Drug Directory" in December 2025 establishes a multi-layered payment system, creating new market pathways for high-value innovative drugs [2]. - Industry insiders are optimistic about 2026, anticipating a surge in innovative drug business development (BD) due to supportive industrial policies for true and high-level innovations [2]. - The dual push from commercial insurance implementation and procurement optimization is expected to sustain high prosperity in the innovative drug industry, with high-value innovative drugs likely to experience a second growth curve [2]. Group 5: Key Companies - Notable companies in the Hong Kong innovative drug sector include: Heng Rui Medicine, Kelun-Botai Biological, and others [3]. - Leading companies in the CXO sector include: Kailai Ying, Kanglong Chemical, and others [4].

冲高回落后全天维持在中轴附近，截至收盘恒生指数微涨0.03%。恒生医疗涨幅居前，恒生互联网、恒 生科技紧随其后，银行逆势回撤。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生医疗高开高走强势爆发，截至收盘大涨5.91%。其中信达生物上涨6.09%，三生制药上涨5.7%，百 济神州上涨5.31%，石药集团、翰森制药等多股涨幅在4%上方。 恒生科技跳空高开后全天维持在高位盘整，截至收盘上涨3.69%。其中快手大涨11.09%，阿里巴巴上涨 2.55%，中芯国际、美团、腾讯控股等均有不错表现。 恒生银行低开低走陷入调整，截至收盘下跌1.16%。包括郑州银行、招商银行、邮储银行、工商银行灯 光均小幅收跌。 ...

截至午间收盘，沪指报4095.54点，涨0.29%，深证成指涨0.35%，创业板指涨0.41%。 大家好，今天是周三，基金君和你继续关注市场行情！ 1月7日上午，A股三大股指集体上涨，沪指冲击4100点，再创10年来新高，市场量能强劲，半日成交额超1.8万亿元。 【导读】上午A股三大指数集体大涨，半导体、稀土板块大涨，光刻机概念股领涨 沪深两市半日成交额达1.84万亿元，较上个交易日放量538亿元。个股跌多涨少，全市场共2522只个股上涨，88只个股涨停，2773只个股下跌。 从板块看，半导体、基本金属、制药、煤炭等板块涨幅居前，光刻机、稀土概念股大涨；锂电电解液、金融科技等板块跌幅居前。 港股方面，在2026年开市大涨后，今天上午恒生指数、恒生科技指数、恒生中国企业指数等出现明显回调，跌幅均超1%。个股方面，腾讯控股跌超2%， 阿里巴巴跌超3%，小米集团、比亚迪（002594）、网易、美的纷纷下跌。恒生生物科技逆市上涨，康方生物、和黄医药涨超5%，翰森制药、亚盛医药、 科伦博泰生物、药明康德（603259）涨超3%。 | 序号 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 | 成交额 | 年初至今 | ...

煤炭板块突然拉升。 A股市场今天（1月7日）上午进一步上行，上证指数逼近4100点。 临近上午收盘，煤炭板块突然拉升，陕西黑猫、安泰集团2分钟直线拉升至涨停，另有多只煤炭股也快速拉升。 值得注意的是，临近中午收盘，煤炭板块突然拉升，陕西黑猫（601015）、安泰集团（600408）2分钟直线拉升至涨停。 煤炭板块突然拉升 A股市场今天（2026年1月7日）上午进一步上行，上证指数逼近4100点。截至中午收盘，上证指数上涨0.29%报4095.54点，深证成 指上涨0.35%，创业板指上涨0.41%。 主要行业板块和赛道方面，若按照申万一级行业划分，电子板块领涨，板块盘中涨幅接近2%，板块内个股掀起涨停潮，其中南大 光电（300346）、芯源微等多股20%涨停，另有多股涨停或涨幅超过10%。 有色金属板块涨幅居前，中科磁业（301141）、中稀有色（600259）、翔鹭钨业（002842）等多股盘中涨停。 综合、通信、建筑装饰等板块涨幅居前。 石油石化板块领跌，中国海油（600938）跌幅超过4%，中国石油跌幅超过3%，领跌该板块。 概念板块方面，光刻机、存储芯片、镍金属等概念大幅上涨。 多只个股连续涨停 在上 ...

煤炭板块突然拉升。 A股市场今天（1月7日）上午进一步上行，上证指数逼近4100点。 值得注意的是，临近中午收盘，煤炭板块突然拉升，陕西黑猫、安泰集团2分钟直线拉升至涨停。 煤炭板块突然拉升 A股市场今天（2026年1月7日）上午进一步上行，上证指数逼近4100点。截至中午收盘，上证指数上涨0.29%报4095.54点，深证成指上 涨0.35%，创业板指上涨0.41%。 主要行业板块和赛道方面，若按照申万一级行业划分，电子板块领涨，板块盘中涨幅接近2%，板块内个股掀起涨停潮，其中南大光电、芯 源微等多股20%涨停，另有多股涨停或涨幅超过10%。 临近上午收盘，煤炭板块突然拉升，陕西黑猫、安泰集团2分钟直线拉升至涨停，另有多只煤炭股也快速拉升。 | 今开 | 4.25 最高 | 4.55 成交量 | 163.47万手 | 总市值 ▼ | 45.81亿 | 量比 | | 4.14 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 昨收 | 4.14 最低 | 4.22 成交额 | 7.18亿 | 总股本 | 10.07亿 | 载比 | | 10 ...

Group 1 - The core viewpoint of the news is that the Hong Kong stock market's innovative drug index is experiencing growth, indicating a positive trend in the pharmaceutical sector, particularly in innovative drugs [1] - As of 09:40, the Hong Kong Stock Connect innovative drug index rose by 1.59%, with individual stocks like Kangfang Biotech increasing over 3%, and others such as Kelun-Bio, CSPC Pharmaceutical, and Hansoh Pharmaceutical rising over 2% [1] - The report from Donghai Securities suggests that by 2026, China's pharmaceutical and biotechnology industry will enter a new era of innovative drugs, which will gradually dominate the sector, supported by the complementary relationship between medical insurance and commercial insurance [1] Group 2 - The Hong Kong Stock Connect innovative drug ETF, managed by Harvest (520970), tracks the CSI Hong Kong Stock Connect Innovative Drug Index, with the top ten weighted stocks accounting for over 71.71% of the total weight [2] - The management and custody fees for the Harvest innovative drug ETF are 0.60% per year, making it suitable for both ordinary investors as a long-term investment tool and for professional investors seeking flexible trading options [2]

2026年1月7日，恒生医药ETF（159892）上涨2.94%，冲击三连阳。持仓股康方生物、和黄医药、翰森 制药涨超4%。 中信建投证券认为，国内上市药企正迎来创新收获期，呈现自主研发+海外BD双轮驱动格局。整体看， 中国药企从单一市场驱动转向全球价值创造，JPM大会将成为展示临床数据、洽谈海外合作的核心舞 台。 恒生医药ETF（159892）聚焦创新药、CXO及相关产业，港交所18A制度优势下覆盖众多创新标的（百 济神州、信达生物等），在创新药出海+商保目录等催化下有望延续估值修复行情。 消息面上，近日，国家药监局官方微信公号发文称，2025年我国已批准上市的创新药达76个，大幅超过 2024年全年48个，创历史新高。此外，2025年我国创新药对外授权交易总金额超过1300亿美元，授权交 易数量超过150笔，同样创历史新高。 ...

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) experienced significant net redemptions, indicating a trend of outflow in the cross-border ETF market [1][2]. Group 1: Fund Performance - As of January 6, the fund's latest scale is 50.48 billion yuan, with a net outflow of 926.56 million yuan on that day, representing 0.18% of the previous day's scale [1]. - Over the past five days, the fund faced net redemptions totaling 942.76 million yuan, ranking 16th out of 207 in cross-border ETF net outflows [1]. - Year-to-date, the fund's share count decreased by 0.32% from 37.63 billion shares on December 31, 2025, while its scale increased by 6.24% [2]. Group 2: Liquidity and Trading Activity - The cumulative trading amount over the last 20 trading days reached 87.66 billion yuan, with an average daily trading amount of 4.38 billion yuan [2]. - In the first two trading days of the year, the cumulative trading amount was 11.7 billion yuan, averaging 5.85 billion yuan per day [2]. Group 3: Fund Management and Holdings - The current fund managers are Liu Weilin and Jiao Wendong, with returns of 34.57% and 53.37% respectively during their management periods [2]. - Major holdings in the fund include companies like 百济神州 (10.84%), 康方生物 (10.77%), and 信达生物 (10.43%), with significant market values for each [2].

Group 1: Market Performance - Hong Kong's innovative drug ETF (159570) surged by 3%, with a trading volume exceeding 1.5 billion yuan, following a net inflow of over 62 million yuan today after a previous inflow of 430 million yuan [1][3] - As of January 6, the latest scale of the Hong Kong innovative drug ETF reached over 23.3 billion yuan, leading its peers in the same category [1] Group 2: Economic Signals - Federal Reserve Governor Milan indicated that upcoming economic data may support further interest rate cuts, with expectations of a reduction exceeding 100 basis points this year [3] - Wall Street analysts suggest that if the U.S. unemployment rate rises to 4.7% by December 2025, the Fed may cut rates by 25 basis points this month [3] Group 3: Company Developments - Brain-computer interface "unicorn" Strong Brain Technology completed a financing round of 2 billion yuan, second only to Musk's Neuralink [3] - AI pharmaceutical company Insilico Medicine announced a long-term collaboration with Siveya for anti-tumor drug development, with a total deal value of 888 million USD [3] Group 4: New Drug Approvals - On January 6, BeiGene announced that its self-developed BCL2 inhibitor, Baiyueda® (sotucumab), received conditional approval from the National Medical Products Administration [3] - Shiyao's SYS6017 has initiated Phase II clinical trials for the prevention of shingles [3] Group 5: Investment Insights - Zhongtai Securities predicts that the pharmaceutical sector's opportunities in 2025 will focus on innovation and industry upgrades, with investment strategies continuing into 2026 [5] - The report emphasizes the importance of "innovative drugs and industry chains, demand recovery, and AI" as key investment dimensions [5] Group 6: J.P. Morgan Healthcare Conference - The 44th J.P. Morgan Healthcare Conference is set to take place from January 12 to 15, 2026, in San Francisco, attracting over 8,000 global participants [6] - The conference will feature over 500 listed companies and thousands of startups, focusing on "capital + strategy" discussions [6] Group 7: Industry Trends - Three major trends are highlighted for 2026: the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the emergence of new market forces [7] - The report notes that over 20 gene editing companies will showcase breakthroughs in CAR-T and base editing at the conference [7] Group 8: MNC Engagement - Multinational corporations (MNCs) are willing to pay higher prices for innovative drugs from China, with the average total package for drugs purchased from China being 2.76 billion USD, compared to 1.29 billion USD for those from overseas [8] - The willingness of MNCs to pay a premium for Chinese innovations is driven by the need to fill significant pipeline gaps due to impending patent expirations [8] Group 9: Investment Focus - Investment strategies should focus on companies with strong clinical development capabilities and those in popular therapeutic areas such as ADCs, GLP-1, and dual antibodies [11] - Companies that can produce high-quality late-stage clinical assets are likely to attract MNC interest [11] Group 10: Key Therapeutic Areas - The report identifies key therapeutic areas for investment, including ADCs, GLP-1, dual antibodies, and neuroscience, emphasizing the need for innovative platforms and clinical data superiority [12]

Investment Rating - The report assigns an "Outperform" rating to multiple stocks in the Hong Kong healthcare sector, including Hansoh Pharma, 3SBio, Kelun-Biotech, Innovent Biologics, Akeso, JD Health, WuXi AppTec, and BeiGene [1][4][37]. Core Insights - The rollout of the "dual formulary" system, which includes the National Reimbursement Drug List (NRDL) and the inaugural Commercial Innovation Drug List, is expected to significantly benefit the innovative drug value chain. The NRDL added 114 drugs with an 88% success rate, up from 76% in 2024, while the commercial list includes 19 innovative drugs [7][40]. - The report highlights three key features of the new drug lists: a focus on innovation, addressing the needs of the elderly and children, and reinforcing the distinction between basic and commercial insurance coverage [7][40]. - The report expresses a long-term positive outlook on the innovative drug value chain, driven by state support for novel drugs and the inclusion of high-innovation therapies in the commercial insurance list [7][40]. Summary by Sections Stock Recommendations - The report lists several top picks for January 2026, including Hansoh Pharma, 3SBio, Kelun-Biotech, Innovent Biologics, Akeso, JD Health, WuXi AppTec, and BeiGene, all rated as "Outperform" [1][4][37]. Market Performance - The December 2025 portfolio of Hong Kong "Golden Picks" saw an average decline of 12.4%, underperforming the Hang Seng Healthcare Index, which fell by 9.5% [5][38]. - Notable performers in December included WuXi AppTec, Akeso, and JD Health, which experienced smaller declines compared to the overall portfolio [5][38]. Industry Trends - The healthcare services sector is noted as undervalued, with companies like Hygeia and Jinxin Fertility showing strong performance due to ongoing market buy-backs [8][41]. - The report suggests monitoring the recovery opportunities in the consumer healthcare sector for 2026, particularly in light of low base effects [8][41]. Recent Developments - A series of business development (BD) deals in December 2025 indicates sustained interest from multinational corporations (MNCs) in the biotech and pharmaceutical sectors, with significant upfront payments and milestone agreements [10][43][44]. - The report emphasizes the attractiveness of the biotech sector following recent valuation resets, suggesting potential for pre-earnings catch-up trades [10][42].